IA
KNSA icon

IFP Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

IFP Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.18K Sell
81
-1
-1% -$52 ﹤0.01% 3773
2026
Q1 		$3.95K Hold
82
– – ﹤0.01% 3658
2025
Q4 		$3.38K Buy
82
+7
+9% +$281 ﹤0.01% 3618
2025
Q3 		$2.91K Buy
75
+1
+1% +$32 ﹤0.01% 3534
2025
Q2 		$2.05K Buy
74
+52
+236% +$1.32K ﹤0.01% 3889
2025
Q1 		$489 Hold
22
– – ﹤0.01% 3466
2024
Q4 		$435 Buy
+22
New +$502 ﹤0.01% 3457
2023
Q4 		– Sell
-3,750
Closed -$65.1K – 3207
2023
Q3 		$65.1K Buy
+3,750
New +$63.2K ﹤0.01% 1448

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

IFP Advisors's KNSA Position: Q2 2026 in Review

IFP Advisors reduced its Kiniksa Pharmaceuticals (KNSA) stake by 1.2% in Q2 2026, selling an estimated $52 and leaving 81 shares worth $5.18K. The position accounts for ﹤0.01% of the portfolio, ranked #3773.

IFP Advisors first reported a position in KNSA in Q3 2023 and has held it in 8 quarters since. The position peaked at $65.1K in Q3 2023. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • IFP Advisors held 81 shares of Kiniksa Pharmaceuticals worth $5.18K as of Q2 2026.
  • IFP Advisors sold 1 Kiniksa Pharmaceuticals share in Q2 2026, an estimated $52.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3773 holding.
  • IFP Advisors first reported a position in Kiniksa Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
  • IFP Advisors's Kiniksa Pharmaceuticals position peaked at $65.1K in Q3 2023.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.